XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue Recognition (Tables)
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Timing of Revenue Recognition
The following table illustrates the timing of the Company’s revenue recognition patterns:
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Software products and services – point in time40.3 %37.0 %43.0 %36.8 %
Software products and services – over time50.0 30.9 41.5 26.6 
Drug Discovery – point in time— — 7.6 19.1 
Drug Discovery – over time9.7 32.1 7.9 17.5 
Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue
The following table presents the revenue recognized from the sources of software products and services revenue:
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
On-premise software$12,250 $13,806 $48,627 $50,564 
Hosted software8,814 5,463 24,077 14,366 
Software maintenance5,658 5,752 17,393 17,378 
Professional services2,038 2,083 7,482 6,361 
Revenue from contracts with customers28,760 27,104 97,579 88,669 
Software contribution3,124 1,800 3,124 1,800 
Total software revenue$31,884 $28,904 $100,703 $90,469 
Drug Discovery Revenue
The following table presents the revenue recognized from the sources of drug discovery revenue:
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Drug discovery services revenue from contracts with customers$2,813 $12,730 $17,012 $49,765 
Drug discovery contribution593 935 1,507 2,306 
Total drug discovery revenue$3,406 $13,665 $18,519 $52,071 
Schedule of Contract Balances
Contract balances were as follows:
As of
September 30,
2024		As of
December 31,
2023
Contract assets$30,528 $21,107 
Deferred revenue, short-term:
Software products and services32,978 44,218 
Drug discovery8,795 12,013 
Deferred revenue, long-term:
Software products and services1,862 2,407 
Drug discovery3,338 6,636